Business Wire

Zilliant Unveils Next-Generation Price IQ ® : The Market’s Fastest and Most Transparent Price Optimization Application

Share

Zilliant, the industry leader in intelligent end-to-end pricing solutions and sales guidance software, today announced Next-Generation Price IQ®, the next giant leap for its market-leading B2B price optimization solution.

Inflation has become the new business reality, exacerbated by supply chain turmoil, increased competition, and dramatic swings in both demand and inventory availability. As a result, B2B companies need a faster, more powerful approach to pricing that maintains market alignment while generating prices that are easily explainable and defensible.

Next-Generation Price IQ® delivers huge advances in performance, with a 10x improvement in AI-based optimization speeds. Now, businesses can quickly respond to rapidly changing business dynamics and market changes while providing unprecedented price transparency to sales teams.

“Leading the market in price optimization for two decades has revealed one critical truth: If sales reps don’t understand how a price is generated, they are unlikely to use it,” said Zilliant President and Chief Executive Officer Greg Peters. “That’s why I’m thrilled to announce today that Next-Generation Price IQ® provides a way to keep prices competitive amid near-constant change while also providing a pragmatic means to leverage AI with a crystal-clear view into how prices were derived.”

Other B2B pricing solutions make it impossible to understand how pricing was derived by tucking parameters, complex AI, and formulas out of sight and out of reach for users, or they generate pricing using strict rules that break as complexity increases. These methods fail to address volatile and competitive B2B markets.

In stark contrast, Next-Generation Price IQ® offers a transparent, proven and pragmatic pricing solution using data science and AI that’s both sophisticated and flexible. Most importantly, Zilliant is helping embroiled B2B companies navigate a supply-constrained, pandemic-disrupted, and inflationary time to meet and exceed their margin and revenue goals.

Zilliant’s next generation of price optimization empowers pricing teams to:

  • Conduct goal-seeking, what-if scenarios to align business goals with pricing strategies
  • Enforce rational price relationships such as minimum margin requirements and good-better-best product relationships
  • Simultaneously visualize the predicted margin, revenue and volume impacts for various what-if scenarios before publishing optimized prices
  • View precisely how the optimization engine produced each price, drill into each optimized price, view the associated transactions with inline analytics, make adjustments, and see how price changes will impact revenue and profit
  • Immediately publish prices into CRM, CPQ, ERP, eCommerce or any other commercial system

No other price optimization solution in B2B can measure price elasticity, enforce rational price relationships, and conduct goal-seeking what-if scenarios in B2B. Where other applications use sequential rules or if-then statements, Next-Generation Price IQ® takes full advantage of constraint-based optimization to simultaneously account for business rules and price relationship requirements. Additionally, Zilliant is the only price optimization and management software company to offer a dedicated customer success team of industry, pricing, and data science experts to act as a strategic partner, delivering continuous value, change management guidance and precise measurement of adoption metrics, margin and revenue drivers, KPI trends, and pricing opportunity analyses.

Customers have reported a 10x ROI in less than a year with Zilliant’s price optimization solution; Next-Generation Price IQ® can be up and running in 90 days and lowers overall cost by supporting multiple pricing models and scenario templates, enabling simultaneous optimization of multiple lines of business within the same instance.

To learn more about Next-Generation Price IQ®, visit https://www.zilliant.com/products/priceiq.

About Zilliant

Zilliant powers intelligent commerce for B2B companies by connecting their commercial strategies with effective execution. Our industry-leading price optimization and management and sales guidance software enables profitable growth by transforming the way our customers use data to price and sell in traditional and digital channels. Zilliant’s data science, cloud-native software and passion for customer success delivers the highest ROI, fastest time to value and highest customer satisfaction. Learn more about how Zilliant helps power intelligence commerce at www.zilliant.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Treble
Matt Grant
zilliant@treblepr.com

Danielle Schulz-Behrend
dschulzbehrend@zilliant.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Align Announces Additional Leadership for UK and EMEA to Support Continued Growth18.5.2022 17:11:00 CEST | Press release

Align, the premier global provider of technology infrastructure solutions celebrates significant growth throughout the UK and EMEA markets with management changes to support increasing demand. The appointment of Giulia Marcolina as Managing Director and Mike Konold as AV Solutions Director of Align’s UK-based headquarters, will enable the team to deliver innovative collaborative technology and state-of-the-art AV solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220518005833/en/ Giulia Marcolina, a 15 year veteran with Align, is named Managing Director of Align's UK-based headquarters. (Photo: Business Wire) Giulia brings over 25 years of IT experience, previously serving as Align’s Programme Manager, delivering corporate office relocation and consolidation projects for clients such as Blackrock, Total Gas and Power, and UBS. In her new role, she will lead Align’s team of project managers in building upon Align’s lon

RMS Advances Climate Risk Modeling and Moves More Models to High Definition18.5.2022 16:30:00 CEST | Press release

RMS®, a Moody’s Analytics company and world-leading risk modeling and solutions company, today announces it will be releasing four new High Definition™ (HD) models, including Europe Windstorm, North America Winterstorm (WT), North America Severe Convective Storm (SCS), and Terrorism. RMS HD Models represent the next generation of risk modeling, delivering deeper analysis and granularity from Moody’s. The HD probabilistic models incorporate a high-fidelity, simulation-based framework for modeling event frequency and severity, to provide a major step forward in the quality of catastrophe risk quantification. The framework allows for event footprints to be represented more realistically across larger event sets. The new RMS Europe Windstorm HD Model further enhances the current model and will cover 17 countries, adding Finland and Lichtenstein. The HD model includes a climate variability view and has expanded storm surge analytics to include the U.K., Ireland, France, and Belgium. Storm c

Suketu Upadhyay Elected to Vertex Board of Directors18.5.2022 16:30:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Suketu (“Suky”) Upadhyayhas been elected to its board of directors as an independent director. Mr. Upadhyay is a global business executive with more than 20 years of experience in the pharmaceutical and medical technology sectors, serving in financial and strategy roles covering multiple areas of the life sciences sector. He is currently the Executive Vice President and Chief Financial Officer of Zimmer Biomet, a leading global innovator and manufacturer of orthopedic solutions, a position he has held since July 2019. “We are delighted to have Suky join the Vertex Board. His extensive financial and strategic experience in health care, paired with his leadership and expertise across biopharma and medtech, make him a valuable addition to our board of directors,” said Reshma Kewalramani, M.D., Vertex’s Chief Executive Officer and President. “It’s an honor to join Vertex, a company focused on serial innovation with an

Armory Makes Continuous Deployment Achievable and Effortless, at any Scale, for all Developers18.5.2022 16:17:00 CEST | Press release

Armory, the Continuous Deployment company empowering development teams to easily, reliably, safely, and continuously deploy software at any scale, today announced public early access to their new Continuous Deployment-as-a-Service product. Armory Continuous Deployment-as-a-Service delivers declarative deployments, across multiple environments, that support advanced strategies, so developers can focus on building great code rather than deploying it. “We believe deploying software continuously, at any scale, should be achievable and effortless for all developers of the world, not just the likes of Google and Netflix,” said Jim Douglas, President and CEO, Armory. “It’s our vision and mission to unlock innovation through software to make software continuous, scalable, secure, and safe, so developers can improve and protect their customers’ experience with confidence and ease.” To effectively compete in a software-defined world, development teams must ensure a stellar customer experience. S

Sermo Survey Reveals New Lung & Breast Cancer Research Rated as Most Interesting by Oncologists Attending ASCO This Year18.5.2022 15:15:00 CEST | Press release

A new survey from Sermo, a physician-first online community and leader in global HCP insights, timed to the annual American Society of Clinical Oncology (ASCO) conference found that nearly half (47%) of attending oncologists are most interested in new data being presented about lung cancer. This is followed by a similarly high interest in new data about breast cancer, as reported by 44% of oncologists surveyed. Additionally, oncologists/hematologists reported they are most excited about learning about tumor targeting antibodies treatments as reported by 54% of those surveyed. Ahead of ASCO’s Annual Meeting, new cancer research and innovations are the driving reason surveyed oncologists/hematologists are attending the conference this year (59%). However, how they plan to attend looks different to many oncologists, as only 18% of oncologists/hematologists surveyed said they will attend ASCO in-person this year. A Look Into the Pandemic’s Negative Impacts on Cancer Care Globally Oncologis

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom